K
Keshab Sarma
Researcher at Hoffmann-La Roche
Publications - 46
Citations - 1281
Keshab Sarma is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Hepatitis C virus & Prodrug. The author has an hindex of 15, co-authored 46 publications receiving 1228 citations.
Papers
More filters
Patent
Matrix metalloprotease inhibitors
Bender Steven Lee,Chris Allen Broka,Campbell Jeffrey Allen,Castelhano Arlindo L,Lawrence E. Fisher,Robert Than Hendricks,Keshab Sarma +6 more
TL;DR: In this paper, the authors used matrix metalloproteases, such as stromelysin, gelatinase, matrilysin and collagenase, for the treatment of disease states.
Journal ArticleDOI
The Novel Nucleoside Analog R1479 (4′-Azidocytidine) Is a Potent Inhibitor of NS5B-dependent RNA Synthesis and Hepatitis C Virus Replication in Cell Culture *
Klaus Klumpp,Vincent Leveque,Sophie Le Pogam,Han Ma,Wen-Rong Jiang,Hyunsoon Kang,Caroline Granycome,Margaret Singer,Carl Laxton,Julie Qi Hang,Keshab Sarma,David Bernard Smith,Dieter Heindl,Christopher John Hobbs,John Herbert Merrett,Julian Symons,Nick Cammack,Joseph A. Martin,Rene Devos,Isabel Najera +19 more
TL;DR: Hepatitis C virus (HCV) polymerase activity is essential for HCV replication and the corresponding 5′-triphosphate derivative (R1479-TP) is a potent inhibitor of native HCV replicase isolated from replicon cells and of recombinant HCV polymerase (NS5B)-mediated RNA synthesis activity.
Patent
Antiviral nucleoside derivatives
TL;DR: In this paper, a process for preparing 1,3,4'-triacyl pyrimidine nucleoside from a N,1, 3, 4, 4'-tetraacylpyrimidine nucleus is described.
Journal ArticleDOI
Design, synthesis, and antiviral properties of 4′-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479
David Bernard Smith,Joseph Armstrong Martin,Joseph Armstrong Martin,Klaus Klumpp,Stewart J. Baker,Peter Blomgren,Rene Devos,Caroline Granycome,Caroline Granycome,Julie Hang,Hobbs Christopher John,W.R. Jiang,W.R. Jiang,Carl Laxton,Sophie Le Pogam,Vincent Leveque,Han Ma,Graham Maile,JH Merrett,Arkadius Pichota,Keshab Sarma,Mark D. Smith,Steven Swallow,Julian Symons,David R. Vesey,I. Najera,I. Najera,Nick Cammack +27 more
TL;DR: A series of 4'-substituted ribonucleoside derivatives has been prepared and evaluated for inhibition of hepatitis C virus RNA replication in cell culture and the most potent and non-cytotoxic derivative was compound 28 (4'-azidocytidine, R1479).
Journal ArticleDOI
Structure-Based Drug Design of RN486, a Potent and Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
Yan Lou,Xiaochun Han,Andreas Kuglstatter,Rama K. Kondru,Zachary Kevin Sweeney,Michael Soth,Mcintosh Joel,Renee Litman,Judy M. Suh,Buelent Kocer,Dana Davis,Jaehyeon Park,Sandra Frauchiger,Nolan James Dewdney,Hasim Zecic,Taygerly Joshua Paul Gergely,Keshab Sarma,Hong Jun-Bae,Ronald J. Hill,Tobias Gabriel,David Michael Goldstein,Timothy D. Owens +21 more
TL;DR: Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis, resulting in compound 1 (RN486), which was selected for advanced preclinical characterization based on its favorable properties.